CD8A and neoplasm: Our studies showed that targeting BCL9/BCL9L facilitates antigen presentation and tumor infiltration of cDC1, as well as boosts tumor infiltration of CD8+ T cells, indicating a critical role of targeting BCL9/BCL9L in overcoming immunotherapy resistance.